Affimed raises $14 million from J&J through innovative deal

Affimed Therapeutics and Johnson & Johnson have entered a collaboration under a novel deal structure that sees Affimed receive cash for an early-stage discovery program, while J&J gets to fund research directly from its balance sheet, a major tax advantage.